With the PDUFA date for Johnson & Johnson's (JNJ +1.68%) SGLT-2 inhibitor Invokana just around the corner, the FDA will soon deliberate on another Type 2 diabetes drug that belongs to the same class: Eli Lilly's (LLY +1.53%) empagliflozin. Can these drugs get the green light, or will the FDA require both companies to run more clinical trials? Is the FDA's rejection of Forxiga, an SGLT-2 inhibitor developed by Bristol-Myers Squibb (BMY 0.02%) and AstraZeneca (NYSE: AZN), a signal that these drugs will face an uphill battle during the approval process? Health-care analyst Max Macaluso discusses these topics in the following video.
